Effects of Oral PEG 3350 on Electrolyte Balance

This study has been completed.
Sponsor:
Information provided by:
Norgine
ClinicalTrials.gov Identifier:
NCT00868985
First received: March 24, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted

March 24, 2009
March 24, 2009
January 2008
August 2008   (final data collection date for primary outcome measure)
Electrolyte profile in blood, urine and faeces, serum osmolality and effect on the renin/aldosterone ratio [ Time Frame: Ten days ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Amount of PEG 3350 in plasma, urine and faeces [ Time Frame: Ten days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Effects of Oral PEG 3350 on Electrolyte Balance
Effects of Oral PEG 3350 on the Electrolyte Balance in Patient Volunteers With Chronic Constipation:Pharmacokinetic Evaluation

The study is to evaluate the influence of three different doses of PEG 3350 with or without electrolytes on the electrolyte balance in patient volunteers with confirmed chronic constipation.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Chronic Constipation
  • Drug: PEG 3350 plus electrolytes
    Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
  • Drug: PEG 3350 without electrolytes
    Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
  • Experimental: PEG 3350 plus electrolytes
    Patients were dosed with PEG 3350 with electrolytes
    Intervention: Drug: PEG 3350 plus electrolytes
  • Experimental: PEG 3350 without electrolytes
    Patients were dosed with PEG 3350 without electrolytes
    Intervention: Drug: PEG 3350 without electrolytes
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
114
Not Provided
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The subjects written informed consent must be obtained prior to inclusion.
  2. Male and female patients between 18 and 70 years of age with confirmed chronic constipation after the run-in period; this is defined as patients who have recorded in their diaries less than 3 bowel motions/week plus one of the following symptoms:

    Straining during at least 25% of defecations Lumpy or hard stools with at least 25% of defecations Sense of incomplete evacuation with at least 25% of defecation Sensation of ano-rectal blockage with at least 25% of defecation Manula manoeuvres of facilitate at least 25% of defecation

  3. Willing and able to follow the entire procedure and to comply with the study instructions.
  4. For the subgroup of patient volunteers taking ACE-inhibitors (36 subjects): A history of hypertension, with blood pressure controlled to acceptable levels by a stable regimen of ACE-inhibitors.

Exclusion Criteria:

  1. Participation in a clinical research study involving investigational drugs or dosage forms within the previous 3 months.
  2. Subjects who have previously been enrolled in this study.
  3. Subjects who are currently or have a history of abuse of alcohol, non-medical drugs, medicinal drugs or other substance abuse eg solvents.
  4. Major surgery in within the last 12 months.
  5. Malignant tumors within the last 5 years.
  6. Uncontrolled blood pressure or terminal cardiac, liver and/or kidney diseases.
  7. Clinical relevant acute gastrointestinal tract disease, including evidence of intestinal perforation or obstruction, paralytic ileus, toxic megacolon, severe inflammatory conditions.
  8. Acute urinary tract conditions, including cystitis.
  9. Patients with diagnosis or evidence of the following diseases: Hypothyroidism, diabetes mellitus, porphyria, pituitary gland insufficiency, pheochromocytoma, glucagonoma, neurological diseases (eg Hirschprung disease, neurofibromatosis, Chagas disease, stroke, autonomous neuropathy, intestinal pseudoobstruction, Multiple sclerosis, medullar injury, Parkinson disease, Shy-Drager syndrome), collagenosis, vasculitis, myopathy (e.g. sclerodermatitis, amyloidosis, dermatomyositis), intoxication with heavy metals (e.g. Pb, As, Hg)
  10. Concomitant medication:

    1. Use of any oral purgatives/laxatives and prokinetics within the last 14 days prior to dosing.
    2. Use of any opioids, anti-cholinergics, tricyclic anti-depressants, MAOIs, Fe preparations, within the 4 weeks prior to dosing.
    3. Use of any Ca-antagonists, Beta-blockers or diuretics within the last 4 weeks prior to dosing.
    4. other medication which in the opinion of the Investigator could interfere with the principal function of the GI tract.
  11. Subject unable to provide written consent.
  12. Failure to satisfy the Investigator of fitness to participate for any other reason, including suspected non-compliance.
  13. Women of childbearing potential, who are not using and not willing to use medically reliable methods of contraception for the entire study duration, unless they are surgically sterilised/hysterectomised or any other criteria considered sufficiently reliable by the Investigator in individual cases.
  14. Patients with electrolytes disturbances or clinical signs of dehydration.
  15. Positive test at screening for HIV or hepatitis.
  16. Any clinically significant abnormal test results.
Both
18 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Romania
 
NCT00868985
PEG-01/2007(ELE)
No
Vice President Clinical Development, Norgine Ltd
Norgine
Not Provided
Study Director: Hans-Jürgen Gruss, MD Norgine
Principal Investigator: Rodica Cinca, MD IFE Human Pharmacology
Norgine
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP